We have a previously reported that interleukin-IO (IL-IO) is a potent but IL-6-unrelated growth factor for freshly explanted myeloma cells (Lu et al, Blood85:2521. We have also shown that exogenous IL-10 supportedthe growth of XG-1 and XG-2 human myeloma cell lines (HMCL) through an IL-6-independent mechanism. (Lu et al, Blood 85:2521. Because the IL-10 receptor does not involve the gp130 IL-6 transducer, we have attempted t o elucidate the mechanisms of IL-10 action on myeloma cells. Our results indicate that the myeloma cell growth factor activity of IL-10 was abrogated by an antibody t o the gp130 IL-6 transducer, indicating that it was mediated through one of the gp130-activating cytokines. We found that myeloma cells from XG-1 and XG-2 HMCL and from 5 of 6 patients' tumoral samples produced oncostatin M (OM) constitutively but failed t o produce IL-6, IL-11 and leukemia-inhibitory factor (LIF). The autocrine OM was inactive in the absence of IL-10 due t o lack of a functional OM receptor on myeloma cells. IL-IO, by in-N HUMANS, FOUR cytokines other than interleukin-6
We have a previously reported that interleukin-IO (IL-IO) is a potent but IL-6-unrelated growth factor for freshly explanted myeloma cells (Lu et al, Blood85:2521 . We have also shown that exogenous IL-10 supportedthe growth of XG-1 and XG-2 human myeloma cell lines (HMCL) through an IL-6-independent mechanism. (Lu et al, Blood 85:2521 . Because the IL-10 receptor does not involve the gp130 IL-6 transducer, we have attempted t o elucidate the mechanisms of IL-10 action on myeloma cells. Our results indicate that the myeloma cell growth factor activity of IL-10 was abrogated by an antibody t o the gp130 IL-6 transducer, indicating that it was mediated through one of the gp130-activating cytokines. We found that myeloma cells from XG-1 and XG-2 HMCL and from 5 of 6 patients' tumoral samples produced oncostatin M (OM) constitutively but failed t o produce IL-6, IL-11 and leukemia-inhibitory factor (LIF). The autocrine OM was inactive in the absence of IL-10 due t o lack of a functional OM receptor on myeloma cells. IL-IO, by in-N HUMANS, FOUR cytokines other than interleukin -6 I (IL-6) use the gp130 IL-6 transducer: ciliary neurotrophic factor (CNTF), leukemia-inhibitory factor (LIF), IL-I 1, and oncostatin M (OM).' In mice, a new gp130 transducer-activating cytokine, cardiotropin-1, was recently identified.27 1L-6 binds first to its specific receptor (IL-6R), and the complex then binds to gp130 and induces its dimerization.' The murine and human receptor genes of IL-I 1 have recently been cloned."' In mice, the complex formed by IL-11 and IL-I1 receptor binds to the gp130 transducer and induces its dimerization as IL-6/IL-6R.5 LIF binds to an LIF receptor (LIFR) of 190 kD molecular weight that forms a heterodimer with the gp 130 tran~ducer.~ CNTF binds first to a specific receptor (CNTFRa), and the CNTFICNTFRa complex then activates a gpl30lLIFR heterodimer.R OM binds to gp130 that forms a heterodimer either with LIFR' or with a new receptor (type I1 receptor) whose sequence is not available. ' Numerous reports have indicated that IL-6 is a potent growtNsurvival factor for malignant plasma cells from mu-ducing the receptor for LIF (LIFR), produced a functional autocrine OM loop in XG-I and XG-2 cells and in primary myeloma cells from 2 patients. We also found that some myeloma cell lines (XG-4, XG-6, and XG-7) an fresh myeloma cells from 3 of 6 patients produced an autocrine IL-10 and that these cells constitutively expressed LIFR. One HMCL (XG-7) produced IL-IO, OM, and IL-6 an expressed LIFR. The XG-7 cells used OM and IL-6 as autocrine growth factors. We have previously shown that IL-10 could induce IL-11 receptor in myeloma cells and confer on them sensitivity t o IL-11 (Lu et al, FEBS Lett 377:515, 1995) . Taken together, these results show that IL-10 is a key cytokine for inducing the expression of LIFR and IL-11R and possibly another uncharacterized OM coreceptor on myeloma cells and that OM and IL-10 might be produced by myeloma cells. They also emphasize that all myeloma cell growth factors reported t o date involve an activation of the gp130 IL-6 transducer.
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rine and human plasmacytomas"' and that IL-6-dependent malignant plasma cell lines can be reproducibly obtained.' OM has been also shown to activate signal transduction in myeloma cells" and induce the proliferation of these cell^.'"'^ In particular, we have shown that the growth of 2 human myeloma cell lines (HMCL), XG-4 and XG-6, is supported by the different gp 130 transducer-dependent cytokines, whereas that of two other HMCL, XG-1 and XG-2, is supported by IL-6 only." One difference is that LIFR and IL-1 1 R are expressed by the XG-4 and XG-6 HMCL, unlike XG-I and XG-2 HMCL.'5.'h Another difference is that XG-4 and XG-6 produce IL-IO, unlike XG-1 and XG-2 HMCL. I' This autocrine IL-IO may explain the sensitivity of XG-4 and XG-6 to IL-11, because exogenous IL-10 can induce IL-I 1 receptor and IL-I 1 responsiveness in XG-I and XG-2 cells that fail to produce IL-10."
We have also recently reported that exogenous IL-I O supported the long-term growth of XG-1 and XG-2 HMCL and had no effect on IL-1 0-producing XG-4 and XG-6 HMCL.I7 Because the IL-10 receptor (IL-10R) does not involve the gpl30 transducer.'X we continued our investigations and established that IL-10 actually induces expression of a coreceptor for OM (LIFR) in myeloma cells, promoting the growth of cells that produce OM spontaneously. The XG-4 and XG-6 HMCL that produced 11,-10 constitutively expressed LIFR and IL-I 1 R but failed to proliferate autonomously because they did not produce OM, LIF, or IL-1 1. We identified one autonomously growing HMCL that produced OM and IL-6 as autocrine growth factors. Finally, studies of freshly explanted tumoral samples showed that OM is frequently produced by primary myeloma cells and that IL-10 could induce their proliferation through an OM autocrine loop. Purijication and cultures of freshly explanted myeloma cells. Mononuclear cells from tumoral samples (MC) were separated on Ficoll Hypaque. Myeloma cells were purified by using the antimyeloma cell B-B4 monoclonal antibody (MoAb). We have shown that the B-B4 MoAb recognizes syndecan-1 and that syndecan-I is present on myeloma cells only in tumoral samples. 19 In addition, this antigen is cleaved by chymopapain without affecting cell viability using a procedure previously described for CD34 purification (B. Klein, unpublished results)." To purify myeloma cells, MC from tumoral samples were suspended in Hanks' buffer containing 1% of human serum albumin (Hanks/HSA) and 0.5% human Ig at a concentration of 2 X lo7 cells/mL and incubated for 30 minutes at 4°C. The B-B4 MoAb was then added (1 pg/ IO6 cells) for 30 minutes at 4°C under gentle agitation. Unbound antibodies were removed by washing (2 times at 400g for 10 minutes in cold), and cells were resuspended in HankslHSA at a concentration of 2 X IO7 cells/mL. Magnetic beads coated with sheep antimouse IgG (Dynal M450; Dynal, Oslo, Norway) were added at a ratio of 4 beads to 1 target cell and incubated for 30 minutes at 4°C under gentle agitation. The beads and rosetted cells were then captured with a magnet (MPCI; Dynal) and washed three times with the initial volume of HanksfHSA to remove nonrosetted cells. Rosetted cells were resuspended in Hanks/HSA at an expected concentration of IO7 cells/mL. Cells were released from the beads using chymopapain (Boots Pharmaceuticals, Nottingham, UK) at 200 picokatalhl for 20 minutes at room temperature under gentle agitation. The beads were captured
with the MPCl magnet and the procedure was repeated twice to ensure maximal bead capture. Myeloma cells were then resuspended in RPMI 1640 medium and 5% of fetal calf serum (FCS). Purified myeloma cells were cultured at lo6 cells/mL in RPMI 1640 supplemented with 2 mmoVL of L-glutamine and 5% of FCS. In some culture groups, recombinant IL-10 (rIL-10; 50 ng/mL) with or without an anti-gpl30 IL-6 transducer MoAb (B-R3, 10 pg/mL) or an anti-IL-6 MoAb (B-E8 MoAb, 10 pg/mL) or an anti-OM neutralizing antibody (AB-295-NA, 10 pg/mL) were added at the beginning of the culture. Control cultures were made with 10 pg/ mL of a mouse-purified IgGl MoAb and 10 pg/mL of purified goat IgG recognizing no human antigens. After 5 days of culturing, cells were counted and harvested. The percentage of myeloma cells in Sphase (LI) was evaluated using a double immunofluorescence procedure.*' Plasma cells were first labeled using anti-K or anti-A Ig lightchain antibodies and then with an anti-S-phase MoAb. At least 5,000 myeloma cells were examined to determine these percentages. This ensured that the lowest LI could be determined with a 30% precision and a P value < .05.
XG-1, XG-2, XG-4, XG-6, and XG-7 cells used in this study possessed cytoplasmic Ig, expressed plasma-cell antigens (Ag; CD38 and B-B4), and lacked the usual B-cell Ag (CD19 and CD20). They were not infected with Epstein-Barr virus. Their detailed characteristics have been reported elsewhere.'' The U937, 5637, MG 63, and SAOS2 cell lines (purchased from the American Type Culture Collection, Rockville, MD) were routinely grown in culture medium (RPMI 1640 medium and 5% FCS). XG cells were grown with 1 ng/mL of IL-6. All cell lines were free of mycoplasma, as assayed by an enzyme-linked immunosorbent assay (ELISA) kit (Boehringer Mannheim, Mannheim, Germany).
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Cell proliferation assay. To investigate the effects of cytokines and antibodies to cytokines on the proliferation of human myeloma cell lines, XG cells were washed once with culture medium, incubated for 5 hours at 37°C in culture medium alone, and washed again twice to remove recombinant bound IL-6. The cells were then cultured in 96-well flat-bottomed microplates for 5 days with either culture medium alone or various cytokines or antibodies to cytokines or gp130 transducer. Tritiated thymidine (2.5 pC1, 25 Ci/mmoVL; CEA, Saclay, France) was added for the last 8 hours of culture, and tritiated-thymidine incorporation was determined as reported elsewhere. 22 To investigate the effects of cytolunes or antibodies to cytokines on the long-term growth of XG cells, cells were washed once with culture medium, incubated for 5 hours at 37°C in culture medium alone, and washed again twice to remove recombinant bound IL-6. To investigate the effects of a neutralizing antibody to IL-10 on their cytokine responsiveness, XG-4 and XG-6 cells were cultured for 15 days with IL-6 (1 ng/mL) and 10 pg/mL of purified goat antibodies to human IL-10 (AB-217-NA). Ten micrograms of this antibody neutralized 5 ng of IL-10. Control cultures were performed with IL-6 (1 ng/mL) and 10 pg/mL of purified goat IgG recognizing no human antignes (control). After 15 days of culture, cells were washed and cultured for 5 days with various concentrations of the different gp130 transducer-activating cytokines with 10 pg/mL of anti-IL-10 antibodies or control goat IgG. Proliferation was assayed as described above.
Phosphothionate-modified antisense and sense oligonucleotides corresponding to nucleotides + 31 to + 50 of IL-10 coding region were also used to inhibit IL-10 production, as previously described.z3 XG-4 and XG-6 cells (104 celldculture well) were cultured with 20 pmoliL of antisense or sense oligonucleotides to IL-10 in the presence of graded concentrations of OM in RPMI1640 culture medium and 5% heat-inactivated FCS. After 5 days of culture, cell proliferation was assayed as above. The IL-10 concentration in the culture supematants was assayed with an ELISA.
Expression of cytokine and cytokine receptor genes by reverse transcription-polymerase chain reaction (RT-PCR).
To study the expression of cytokine or cytokine receptor genes, XG cells were cultured in culture medium supplemented with 1 ng/mL of IL-6 and harvested in exponential growth phase (5 X lo5 cells/mL). Twenty million XG cells were washed and immediately lyzed with thyocyanate guanidium buffer.z4 To study the effect of addition of IL-10 on XG cells, 10 n g h L of IL-10 was added to cultures of XG cells growing with 1 ng/mL of IL-6, without washing the cells. After 24 hours of culture at 37T, cells were spun down and immediately lyzed with thiocyanate guanidium buffer. SAOS2 and 5637 cells were grown in culture medium and then harvested in exponential growth phase. U937 cells were stimulated for 1 day with 10 ng/mL of phorbol myristate acetate (PMA, Sigma Chemicals, St Louis, MO) and 1 pg/mL of lipopolysachanide (LPS; Sigma Chemicals) before harvesting. Peripheral blood mononuclear cells (PBMC) were isolated from citrated peripheral blood by centrifugation in Ficollhypaque solution and cultured for 48 hours at a concentration of lo6 cells/mL in culture medium supplemented with 1 pg/mL of phytohemagglutinin P (PHA-P; Sigma Chemicals). As for XG cells, 20 million harvested cells were immediately lyzed with thiocyanate guanidium buffer.
Total RNA was isolated by the guanidium-CsC1 method." cDNA was synthesized from 1 pg of total RNA using a reverse transcription kit (Promega, Madison, WI). Thirty-five PCR cycles (60 seconds at 94°C 45 seconds at 6 0 T , and 60 seconds at 72OC), followed by 3 minutes of extension at 72"C, were performed using primers designed to amplify the cDNA of interest. We used primers corresponding to nucleotides 345-364 and 621-640 of IL-10 cDNA, 1141-1160 and 1423-1442 of IL-10 receptor cDNA, 1-22 and 607-628 of IL-6 cDNA, 808-827 and 1346-1365 of LIF cDNA, 6-37 and 269-300 of IL-11 cDNA, 83-102 and 674-693 of OM cDNA, 464-483 and 1297-1316 of LIFR (gp190). and 5-24 and 342-361 of p-2 microglobulin cDNA. Fifteen microliters of PCR product was run on a 1% agarose gel, and the bands were vizualized by ethidium bromide staining. In cases of positivity, the specificity of the vizua- Measurement of cytokines in culture supernatants of myeloma cells. Myeloma cells in exponential growth phase when cultured with IL-6 were harvested, washed once, incubated at 37°C for 5 hours in culture medium, and washed again twice to remove bound recombinant IL-6. Cells were then cultured for 2 days at a concentration of 5 X IO' cellslmL in culture medium. Six culture wells were prepared for each culture group. Culture supematants were harvested and stored at -20°C until needed. OM was assayed using an ELISA
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purchased from R&D Systems (Minneapolis, MN), IL-IO using an each L1 considered (L1 < .OI), 5,000X LI was always greater than ELISA provided by Diaclone (Besanqon. France), LIF using an 5. ELISA provided by Dr A. Godard (INSERM U21 I , Nantes, France), and IL-6 using an ELBA provided by Immunotech. IL-I I activity was assayed with a bioassay developed in our laboratory." The RESULTS sensitivity of these different assays was I pg/mL for OM, I pglmL shown), whereas, in agreement with our previous report,I7
Production
rations or cell numbers were compared using a t-test for small samit supported that of XG-l and XG-2 HMCL (Fig 3) . The gpl30 transducer-dependent cytokines. RT-PCR was used to search for the gene expression of the different gp130 transducer-dependent cytokines. LIF and IL-1 1 genes were expressed in relevant control cells, but not in XG-I and XG-2 cells (Fig 4) , whereas the OM gene was expressed in both XG-I and XG-2 cells cultured with IL-6 or IL-IO. IL-6 gene expression was found in XG-I cells and XG-I cells stimulated with IL-IO, but not in XG-2 cells (Fig 4) . No mRNA for IL-I I , LIF, and OM was detected by RT-PCR in XG-4 and XG-6 HMCL (Fig 4) . XG-4 cells expressed IL-6 gene, as did XG-I cells. The production of these cytokines was also searched for by ELISA or bioassay ( Table  I) . No LIF or IL-I I proteins were detected in the culture supernatants of these four HMCL, in agreement with the lack of LIF and IL-11 mRNA. After extensive washing to remove the bound recombinant IL-6 used for cell growth, no IL-6 was found in the culture supernatant of XG-I , XG-2. XG-4, and XG-6 cells. Interestingly, OM was found in culture supernatants of XG-I and XG-2 cells, unlike those of XG-4 and XG-6 cells ( Table I) . (Anti-IL-6 + 11-61 or OM (Anti-OM + OM) were added t o reverse the inhibitory effect of the antibodies. Two culture groups with 10 p g l mL of neutralizing antibodies t o 11-11 (Anti-IL-11) or LIF (Anti-LIFI were also performed. Proliferation was assayed using tritiated thymidine incorporation. Results are the means ? SD of the tritiated thymidine incorporations determined in sextuplate culture wells.
IL-IO
For personal use only. on October 31, 2017. by guest www.bloodjournal.org From by the anti-LIFR MoAb, unlike cells cultured with IL-6. IL-10 failed to increase the expression of E-6R and gp130 IL-6 transducer on these cells as assayed by FACS analysis (results not shown). Finally, the growth activity of IL-10 on XG-1 or XG-2 cells was completely inhibited by a neutralizing antibody to OM, and this inhibition was reversed by adding exogenous OM (Fig 3) . The fact that neutralizing antibodies to IL-6, LIF, or IL-11 had no effect on the growth activity of IL-10 (results not shown) was in agreement with 
the lack of production of LIF and IL-11 by XG-1 and XG-2 cells and with our previously published results for IL-6." Finally, we have checked that the LIFR induced on myeloma cells was functional. XG-1 and XG-2 cells were not sensitive to LIF (Fig 1) . LIF was able to stimulate their proliferation when these cells were cultured with IL-10 and an anti-OM MoAb to block the autocrine OM (Fig 6) . Neutralizing antibodies or antisense oligonucleotides to IL-IO failed to block the sensitivify of XG-4 and XG-6 cells to IL-11, LIF, or OM. Despite 15 days of culture with a potent anti-IL-I0 antibody to neutralize the autocrine IL-I O produced by XG-4 and XG-6 cells, the response of these cells to IL-I 1. LIF, or OM was unaffected (results not shown). Antisense oligonucleotides to IL-IO inhibited the endogenous IL-10 production by XG-4 and XG-6 cells by 70% and 54%, respectively, but failed to inhibit the sensitivity of these cell lines to OM (results not shown). , , , , , , , , , , , , , Table 1 ) . The expression of ILdR, gp130, and LIFR was studied with the MoAb described above.
Autocririe OM arid IL-IO production arid LIFR expression
Using this methodology, we detected no production of IL-6, IL-I 1, and LIF by freshly explanted myeloma cells. Myeloma cells of the six patients expressed IL-6R and gp130. A major finding was that OM was produced by myeloma cells from five of the six patients. For three patients, myeloma cells produced OM but did not produce IL-IO and failed to express LIFR, as was the case with XG-I and XG-2 HMCL (Fig 9) . Myeloma cells from two patients produced OM and IL-IO together and expressed LIFR, a 5 did XG-7 cells (Fig 10) .
Finally, myeloma cells from one patient had the cytokine profile of XG-4 and XG-6 HMCL, ie, lack of OM production, production of IL-IO, and expression of LIFR (Fig 11) . For two patients, we obtained enough cells to purify myeloma cells and to study the effect of exogenous IL-IO in in vitro cultures. (Fig 12) . In addition, IL-IO induced a proliferation of myeloma cells that was unaffected by anti-L-6 antibodies ( Table 2 ). The IL-IO-induced proliferation was inhibited by anti-gpl30 or anti-OM antibodies, indicating that it was mediated through an autocrine OM loop (Table 2) .
DISCUSSION
we have shown here (1) that myeloma cell lines or patients' freshly explanted myeloma cells frequently produced OM, (2) that IL-10 conferred on myeloma cells the responsiveness to OM by inducing the LIFR that forms with gp130 IL-6 transducer a receptor for OM, and (3) that myeloma For personal use only. on October 31, 2017. by guest www.bloodjournal.org From cells might produce IL-10 in association with an expression of LIFR.
These results make it possible to understand our previous data showing that IL-10 is a potent but IL-6-unrelated myeloma cell growth factor.I7 In particular, we reported that the growth of 2 HMCL (XG-1 and XG-2) could be supported by IL-10. We have presently shown that IL-10 induced a functional OM autocrine loop in these cell lines. They produced OM that was inactive due to the lack of expression of an OM coreceptor. IL-10, by inducing LIFR, induced a functional OM receptor. Similar results were obtained with freshly explanted myeloma cells from two patients. IL-IO might also induce the second receptor for OM, whose characteristics are not published. ' We found no upregulation of IL-6R and gp130 by IL-10, possibly because these receptors were already maximally expressed. Because we have previously shown that IL-10 induced IL-11R in myeloma cells and conferred upon them sensitivity to IL-1 I , I b IL-10 appears to be a key cytokine for regulating the expression of the receptors of the gp130 cytokine family.
Another major finding is that IL-10 might be produced by myeloma cell lines or freshly explanted myeloma cells in association with the expression of LIFR. In the present study, we were not able to show that this autocrine IL-IO was responsible for the sensitivity of some myeloma cell lines to the various gp 130-activating cytokines." This is hardly surprising, because the biologic activity of an autocrine cytokine is difficult to inhibit completely even by using potent neutralizing MoAb or antisense oligonucleotides to IL-10. However, the fact that there was a strict correlation between the ability of myeloma cells from cell lines or patients' tumoral samples to produce IL-10 and to express LIFR and the fact that IL-10 can induce LIFR in IL-10 nonproducer myeloma cells strongly suggest that this autocrine IL-10 was responsible for the expression of LIFR (present study) or IL-11Ri6 in some myeloma cells. Thus, the ability of myeloma cells to produce IL-10 might be a key marker for identifying patients whose myeloma cells are sensitive to IL-6 only and patients whose myeloma cells are sensitive to the various gp130-activating cytokines. These cytokines might be produced by myeloma cells (OM) or their tumoral environment. We have previously shown that circulating IL-10 is rarely detected in the plasma of patients with MM, except for patients with plasma cell 1e~kemia.I~ Thus, the methodology we have described here to identify patients with IL-10-producing myeloma cells might be very useful to find out whether these patients have different disease characteristics. The ability of myeloma cells to produce IL-10 and/or OM might be a part of the malignant process or a characteristic of the normal cell from which the malignant cell originates. In particular, IL-10 is produced by some normal B cells,27 but OM production by normal B cells has not yet been reported. For two of the six patients studied, we found myeloma cells with a possible functional autocrine OM loop, ie, production of OM and IL-10 and expression of LIFR and gp130. However, these cells failed to generate cell lines in vitro. Such a functional OM autocrine loop was shown in the XG-7 HMCL together with an IL-6 autocrine loop.
These results, showing that the myeloma cell growth factor activity of IL-10 is exerted through a gpl30-dependent cytokine, emphasize that all myeloma cell growth factors reported so far involve an activation of the gp130 transducer. '8 This suggests that abnormalities in gpl30-mediated signal transduction might be the major oncogenic event yielding to the continuous proliferation of the myeloma stem cell.
How can we reconcile these results with the previous findings of several groups showing that IL-6 is a major tumoral growth factor in vitro (reviewed in Klein et all')? As we have previously pointed out,28 the simplest explanation is that the concentration of biologically active IL-6 in culture supernatants of tumoral samples or in closed tumoral samples in vivo such as ascites or pleural effusions is about 500-to 5,000-fold higher than those of the other myeloma cell growth factors, which may explain why the myeloma cell proliferation in vivo and in vitro is mainly IL-&dependent. This major role of IL-6 is probably strengthened by the high concentration of agonist-soluble IL-6R in the plasma of patients with MM.29 This soluble IL-6R binds IL-6 with the same affinity as membrane IL-6R and induces an activation of gp130 transducer.'" However, it is likely that the other gpl30-activating cytokines might be functional in vivo, particularly when myeloma cells are proliferating in close contact with stromal cells that might produce these gp130-activating cytokines or 1L-10.
We have previously shown that treatment with anti-IL-6 MoAb completely inhibited the in vivo myeloma cell proliferation in some patients.'',32 Failure to respond to treatment was found in patients who produced a too large amount of IL-6 to be neutralized by a single anti-IL-6 MoAb.?? We have developed new strategies that will make it possible to fully neutralize IL-6 activity in vivo.34 Clinical trials with these new antagonists will help to elucidate the relative role of the different gpl30-activating cytokines in association with the ability of patients' myeloma cells to produce IL-10 or not.
Finally, it would also be interesting to investigate whether the property of IL-10 to induce IL-11RI6 and LIFR is restricted to myeloma cells or whether it could be extended to B cells or other cells. In particular, recent data indicate that IL-6 and IL-10 are the two main cytokines involved in the generation of normal plasma cells in vitro in the CD40'5~3h or T-cell-dependent ~ystem.'~.'~ Our results suggest that IL-10 may induce an autocrine loop of a gp130 transduceractivating cytokine in normal B cells and plasma cells. 
